Patient-Reported Quality of Life During Chemoradiation for Intact Pancreas Cancer: a Prospective Registry Study
William G. Breen(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Mark J. Truty(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), William G. Rule(Mayo Clinic in Arizona), Nathan Y. Yu(Mayo Clinic Hospital), Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Krishan R. Jethwa(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Robert C. Miller(Mayo Clinic), J.B. Ashman(Mayo Clinic Hospital)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2019
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530